Browse studies

Find your next paid study

668 recruiting studies matching your filters

A Phase 1 Study of Combination Tovorafenib (DAY101) and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib (DAY101) and Rituximab With Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia

This phase I/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leuk…

Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06965114

Phase 2

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in tre…

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia+23 more

Estimated

Phase 1

A Phase I Non-Randomized Study of TP53 Reactivation With Arsenic Trioxide in Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

This phase I trial tests the safety, side effects, best dose and how well arsenic trioxide works to prevent relapse in patients undergoing allogenic stem cell …

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Estimated

~$10 – $6,250

University of Michigan Rogel Cancer CenterNCT07737769

Phase 2

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.

Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia (SLL)

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06967610

Phase 1

A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies

This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase…

Relapsed/Refractory Hematological MalignanciesRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLLRelapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)+4 more

Estimated

~$10 – $8,750

Phase 2

Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia (The ALIGN-AML Trial)

This is a phase 2 randomized controlled trial to evaluate whether a geriatric assessment (GA)-guided treatment strategy reduces treatment-related toxicity and …

Acute Myeloid Leukemia

Estimated

~$10 – $6,250

University of RochesterNCT07735208

Comparison of the PRAISE -IR ("Phase 2 Study of Personalized r-ATG (Rabbit Anti-thymocyte Globulin) Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (Hematopoietic Cell Transplantation) ", NCT04872595) Study Population With CIBMTR Controls

The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns …

ALL (Acute B-Lymphoblastic Leukemia)AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)

Estimated

~$10 – $1,050

Miltenyi Biomedicine GmbHNCT07717164

Phase 1

A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant

This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-sp…

Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+9 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07020533

Observational

ACCESS-Leukemia: Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention

The purpose of this study is to explore if screening health-related social needs and early social work consultation is feasible and acceptable for adults with …

Leukemia, Acute

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07671209

Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia, Myelodysplastic Syndrome and Myelproliferative Neoplasms

The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have.…

Acute LeukemiaNewly DiagnosedRelapsed

Estimated

~$10 – $750

Memorial Sloan Kettering Cancer CenterNCT02677064

A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidin…

Leukemia, Myeloid, Acute

Estimated

~$10 – $750

Wake Forest University Health SciencesNCT06580106

Observational

The AYA Oncology Self-care Movement: An Influencer-driven Social Media Intervention for Oral Chemotherapy Adherence

This trial will test the impact of a social media intervention for improving oral chemotherapy adherence among adolescents and young adults (AYAs) with acute l…

Acute Lymphobkastic LeukemiaMedication Adherence

Estimated

~$10 – $6,250

Northwestern UniversityNCT07724652